• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Drug-Device Combinations

Abbott makes Lingo OTC CGM available for sale at Walmart

October 21, 2025 By Sean Whooley

Abbott Lingo over-the-counter CGM next to packaging

Abbott (NYSE:ABT) today shared that it made its Lingo biowearable device available for purchase at Walmart stores. This marks the first availability for the over-the-counter continuous glucose monitor (CGM) at a brick-and-mortar retailer. It brings the Lingo device to more than 3,500 Walmart Supercenter locations (in their health and wellness sections) in the U.S. and […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott

Glaukos picks up FDA approval for Epoxia incision-free keratoconus treatment

October 20, 2025 By Sean Whooley

Glaukos logo

Glaukos (NYSE:GKOS) announced today that the FDA approved its Epoxia incision-free alternative to traditional corneal cross-linking procedures. Epoxia offers an advancement in corneal cross-linking for the treatment of keratoconus. Glaukos describes the rare, sight-threatening disease as “currently far too often undiagnosed and untreated.” Aliso Viejo, California-based Glaukos developed Epoxia to eliminate the need for the […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Regulatory/Compliance Tagged With: Glaukos

Dexcom is facing a class action suit related to G7 CGM

October 17, 2025 By Sean Whooley

Dexcom G7 Wearable Top (1)

A class action lawsuit has been filed against Dexcom (Nasdaq:DXCM) in the U.S. District Court for the Central District of California. The lawsuit, led by plaintiff Kelly Grisoli on behalf of all others similarly situated, demands a jury trial for claims that Dexcom’s representations for its latest-generation G7 continuous glucose monitor (CGM) were false, misleading, […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Legal News, Patient Monitoring, Technology Tagged With: Dexcom

Baxter faces investor lawsuit over infusion pumps

October 17, 2025 By Sean Whooley

Baxter logo

Investors have filed a lawsuit claiming Baxter (NYSE:BAX) violated federal securities laws as a result of issues with certain infusion pumps. Bloomberg Law first reported the filing of the lawsuit in Illinois. The class action suit seeks a trial by jury as investors hope to recover damages related to the rollout of its Novum IQ […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Legal News, Technology Tagged With: Baxter

Civica to launch affordable long-acting insulin in pre-filled pens in 2026

October 16, 2025 By Sean Whooley

Civica Logo (1)

Civica announced today that it plans to launch an affordable long-acting insulin in pre-filled pens starting in January 2026. The company plans to launch insulin glargine-yfgn in pre-filled pens at the lowest list price in the current long-acting insulin market. It intends to make the offering available in the U.S. beginning on Jan. 1, 2026. […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Pharmaceuticals Tagged With: biocon, Civica

Abbott CEO expects continued growth in Diabetes Care with Libre 3, dual sensor

October 15, 2025 By Sean Whooley

This is an Abbott marketing image showing its new Libre app running on a smartphone with a Freestyle Libre sensor leaning against it.

Abbott (NYSE:ABT) continues to get a boost in its Medical Devices business from its Diabetes Care unit’s portfolio of continuous glucose monitors (CGMs). In the company’s third-quarter earnings report released today, Abbott — one of the largest medtech companies in the world — fell shy of Wall Street’s sales expectations, but still reported more than 15% […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Technology, Wall Street Beat Tagged With: abbott

Tandem says Abbott FreeStyle Libre 3 integration is ‘coming soon’

October 14, 2025 By Sean Whooley

Tandem t_slim X2 Abbott FreeStyle Libre 3

On social media, Tandem Diabetes Care (Nasdaq:TNDM) said the launch of a new integration for its insulin pump system is near. “It’s almost here! The t:slim X2 insulin pump integration with the FreeStyle Libre 3 Plus sensor, the world’s smallest continuous glucose monitor, is coming soon,” Tandem wrote on LinkedIn. Tandem announced that it was […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott, Tandem Diabetes Care

FDA accepts application for MannKind inhaled insulin in kids

October 13, 2025 By Sean Whooley

MannKind afrezza inhaled insulin in use

MannKind (Nasdaq:MNKD) announced today that the FDA accepted a supplemental biologics license for its Afrezza inhaled insulin. The submission, if ultimately approved, would enable MannKind to bring Afrezza to children and adolescents (aged 4-17). Afrezza is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to slowly bring powder […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance Tagged With: FDA, mannkind

Ypsomed to open first U.S. manufacturing plant in North Carolina

October 10, 2025 By Sean Whooley

Ypsomed plant Holly Springs North Carolina (1)

Ypsomed (SIX:YPSN) announced today that it plans to establish its first manufacturing facility in the U.S. The Swiss drug delivery device maker selected Holly Springs, North Carolina for the location. It plans to invest approximately $249.5 million (CHF 200 million) in the first phase of the plant. It expects the Holy Springs site to supply […]

Filed Under: Business/Financial News, Drug-Device Combinations, Technology Tagged With: Ypsomed

GE HealthCare unveils new anesthesia delivery system

October 10, 2025 By Sean Whooley

GE HealthCare Logo 2025

GE HealthCare (NYSE:GEHC) has unveiled Carestation 850, its next-generation anesthesia delivery system. The FDA 510(k)-pending system aims to help care teams adapt to evolving clinical and operational needs. It could potentially advance anesthesia care through tools, customizable applications and a sleek, space-conscious footprint. Chicago-based GE HealthCare’s FDA submission follows recent CE mark in Europe and […]

Filed Under: Business/Financial News, Drug-Device Combinations, Hospital Care, Technology Tagged With: GE Healthcare

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 28
  • Page 29
  • Page 30
  • Page 31
  • Page 32
  • Interim pages omitted …
  • Page 374
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS